Gyre Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
GYRE Nasdaq 2830 www.gyretx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Gyre Therapeutics, Inc.

Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors - Jan 6th, 2025 12:00 pm
Gyre Therapeutics Third Quarter 2024 Earnings: EPS: US$0.013 (vs US$0.68 loss in 3Q 2023) - Nov 15th, 2024 11:27 am
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update - Nov 13th, 2024 11:00 am
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis - Oct 22nd, 2024 8:05 pm
Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) market cap dropped US$51m last week; Public companies bore the brunt - Oct 4th, 2024 2:20 pm
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference - Oct 1st, 2024 8:05 pm
Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - Sep 4th, 2024 8:05 pm
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update - Aug 13th, 2024 10:00 am
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference - Aug 9th, 2024 11:00 am
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors - Aug 8th, 2024 8:05 pm
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia - Jul 2nd, 2024 8:05 pm
Estimating The Intrinsic Value Of Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Jun 27th, 2024 11:17 am
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology - Jun 18th, 2024 8:05 pm
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension - May 30th, 2024 8:05 pm
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes - May 28th, 2024 8:05 pm
Gyre Therapeutics Reports First Quarter 2024 Earnings - May 11th, 2024 12:25 pm
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - May 9th, 2024 8:10 pm
Public companies are Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) biggest owners and were rewarded after market cap rose by US$137m last week - Apr 27th, 2024 1:02 pm
Gyre Therapeutics Inc (GYRE) Announces Full Year 2023 Financial Outcomes and Business Progress - Mar 28th, 2024 9:32 am
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update - Mar 26th, 2024 10:00 am